Probucol and atherosclerosis in the Watanabe heritable hyperlipidemic rabbit--long-term antiatherogenic effect and effects on established plaques.
We performed two studies to investigate the effect of probucol on atherogenesis in vivo in the Watanabe heritable hyperlipidemic (WHHL) rabbit. In the first study (Study A), probucol was administered to 2-month-old WHHL rabbits, to evaluate its long-term effect. When killed at about 1.5 years of age, the percentage area of aorta covered with atherosclerotic plaque in probucol-treated rabbits was markedly less than that seen in non-treated rabbits (23.0 +/- 11.4% vs. 87.7 +/- 8.1%, M +/- S.D., P less than 0.001). In the second study (study B), administration of probucol was commenced with 8-month-old WHHL rabbits to investigate whether the drug was effective for limiting atherosclerosis in rabbits in which plaques had already developed. When killed after 6 months of treatment, the percentage area of aorta covered with plaque was 38.1 +/- 12.1% in treated rabbits and 82.7 +/- 22.6% in non-treated rabbits (P less than 0.02). Microscopic observations of lesions also supported the effect of probucol. Probucol treatment resulted in a change not only in the size but also the composition of lesions. Thus, probucol was effective in preventing atherosclerosis in long-term studies at both early and late stages.
Nagano
Y
Y
Department of Geriatric Medicine, Faculty of Medicine, Kyoto University, Japan.
Nakamura
T
T
Matsuzawa
Y
Y
Cho
M
M
Ueda
Y
Y
Kita
T
T
D000818:Animals; D001011:Aorta / Q000378:metabolism / Q000473:pathology; D001161:Arteriosclerosis / Q000097:blood / Q000188:drug therapy / Q000517:prevention & control*; D002784:Cholesterol / Q000378:metabolism; D005260:Female; D006949:Hyperlipidemias / Q000150:complications / Q000188:drug therapy* / Q000235:genetics; D008055:Lipids / Q000097:blood; D008297:Male; D011341:Probucol / Q000494:pharmacology*; D011817:Rabbits; D013997:Time Factors
D008055:Lipids; D002784:Cholesterol; D011341:Probucol